News Image

TC BioPharm Announces Complete Response in Minimal Residual Disease (MRD) Patient

Provided By PR Newswire

Last update: Jun 11, 2025

EDINBURGH, Scotland, June 11, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC (NASDAQ: TCBP), a clinical-stage biotechnology company pioneering gamma delta T cell therapies for the treatment of cancer, today announced the first patient treated in Cohort B, presenting with detectable Minimal Residual Disease (MRD), is now in complete molecular remission following treatment with the lead drug candidate TCB008.

Read more at prnewswire.com
Follow ChartMill for more